Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98

Viale, Giuseppe; Regan, Meredith M.; Maiorano, Eugenio; Mastropasqua, Mauro G.; Dell’Orto, Patrizia; Rasmussen, Birgitte; Raffoul, Johnny; Neven, Patrick; Orosz, Zsolt; Braye, Stephen; Öhlschlegel, Christian; Thürlimann, Beat; Gelber, Richard D.; Castiglione‐Gertsch, Monica; Price, Karen N.; Goldhirsch, Aron; Gusterson, Barry A.; Coates, Alan S.

doi:10.1200/jco.2007.11.9453

Cited by 404 publications

(307 citation statements)

References 24 publications

Supporting

Mentioning

289

Contrasting

Unclassified

Order By: Relevance

“…ER ϩ PR Ϫ tumors show greater genomic instability and twice as many DNA copy number gains or losses as compared with ER ϩ PR ϩ and ER Ϫ PR Ϫ tumors [9]. They showed copy number gains within regions 11q13 (68 -72 Mb), 12q14-q15 (63-68 Mb), and 17q21-q25 (45-73 Mb), and copy number losses within regions 11q13-q25 (82-134 Mb) and chromosome 22 [10].…”

Section: Characteristics Of Er ؉ Pr ؊ Breast Cancermentioning

confidence: 99%

“…These tumors are a mixture of three different molecular subtypes [9]: (a) a ϩ/Ϫ tumor associating with a ϩ/ϩ tumor by gene signature, (b) a ϩ/Ϫ tumor associating with a Ϫ/Ϫ tumor by gene signature, and (c) a ϩ/Ϫ tumor not aligned with either a ϩ/ϩ tumor or a Ϫ/Ϫ tumor by gene signature (true ER ϩ PR Ϫ ) (Fig. 5).…”

Section: Characteristics Of Er ؉ Pr ؊ Breast Cancermentioning

confidence: 99%

“…PR levels in that trial were determined by local laboratory assessment [4,9]. A subgroup analysis indicated that AIs may be more effective in patients with ER ϩ PR Ϫ tumors.…”

Section: Arimidex Tamoxifen Alone or In Combinationmentioning

confidence: 99%

See 2 more Smart Citations

A Review of an Unfavorable Subset of Breast Cancer: Estrogen Receptor Positive Progesterone Receptor Negative

Thakkar

Mehta

2011

The Oncologist

View full text Add to dashboard Cite

Estrogen receptor (ER) ؉ progesterone receptor (PR) ؊ tumors are a distinct subset of breast cancers characterized by aggressive behavior and tamoxifen resistance in spite of being ER ؉ . They are categorized as luminal B tumors and have greater genomic instability and a higher proliferation rate. High growth factor (GF) signaling and membranous ER activity contribute to the aggressive behavior of these tumors. The absence of PR is attributable to low serum estrogen, low levels of nuclear ER, and features of molecular crosstalk between GFs and membranous ER. PR expression is also downregulated by expression of mutated epidermal growth factor receptor (EGFRvIII). This subset of patients has greater expression of human epidermal growth factor receptor (HER)-1 and HER-2 and active GF signaling mediated by the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin pathway. Currently, aromatase inhibitors, fulvestrant, and chemotherapy may be the favored treatment approaches for this subset of patients. Overcoming tamoxifen resistance with targeted therapies such as gefitinib is being evaluated and strategies involving short courses of tamoxifen have been postulated for prevention of recurrence of this subtype. Understanding the interplay between molecular endocrinology and tumor biology has provided experimental therapeutic insights, and continued work in this area holds the promise of future advances in prognosis. The Oncologist 2011;16:276 -285

show abstract

Section: Characteristics Of Er ؉ Pr ؊ Breast Cancermentioning

confidence: 99%

Section: Characteristics Of Er ؉ Pr ؊ Breast Cancermentioning

confidence: 99%

See 1 more Smart Citation

A Review of an Unfavorable Subset of Breast Cancer: Estrogen Receptor Positive Progesterone Receptor Negative

Thakkar

Mehta

2011

The Oncologist

View full text Add to dashboard Cite

show abstract

“…Among postmenopausal women, earlier studies have shown a significant trend in reduction of recurrence rate with higher ER levels among tamoxifen treated, supporting the significance of stronger ER content in endocrine treatment [5][6][7][8].…”

Section: Discussionmentioning

confidence: 92%

“…Remaining research questions include the benefit of LHRH agonists, in addition to tamoxifen, and if LHRH agonists have a role among those not achieving amenorrhea during cytotoxic chemotherapy. Moreover, efficacy of endocrine treament in relation to estrogen receptor (ER) status is mainly established among postmenopausal women, and the different endocrine milieu in premenopausal women may affect the predictive ability of ER status [5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer

Sverrisdóttir

Johansson

et al. 2011

Breast Cancer Res Treat

View full text Add to dashboard Cite

Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer. Breast Cancer Research and Treatment, Springer Verlag, 2011, 128 (3) Abstract: Ovarian ablation improves survival in premenopausal early breast cancer, but the potential added value by luteinizing hormone-releasing hormone (LHRH) agonists to tamoxifen, is still not clear. The purpose of our study is to examine the efficacy of the LHRH agonist goserelin for adjuvant therapy of premenopausal breast cancer, the role of interaction between goserelin and tamoxifen, and the impact of estrogen receptor (ER) content. A total of 927 patients were included in the Stockholm part of the Zoladex in Premenopausal Patients (ZIPP) trial. They were randomly allocated in a 2 x 2 factorial study design to goserelin, tamoxifen, the combination of goserelin and tamoxifen or no endocrine therapy for 2 years, with or without chemotherapy. This is formally not a preplanned subset analysis presenting the endpoint first event. In this Stockholm sub-study, at a median follow up of 12.3 years, goserelin reduced the risk of first event by 32 % (P = 0.005) in the absence of tamoxifen, and tamoxifen reduced the risk by 27 % (P = 0.018) in the absence of goserelin. The combined goserelin and tamoxifen treatment reduced the risk by 24 % (P = 0.021) compared to no endocrine treatment. In highly ER positive tumours, there were 29% fewer events among goserelin treated (P = 0.044) and a trend towards greater risk reduction depending on the level of ER content. The greatest risk reduction from goserelin treatment was observed among those not receiving tamoxifen (HR: 0.52, P = 0.007). In conclusion, goserelin as well as tamoxifen, reduces the risk of recurrence in endocrine responsive premenopausal breast cancer. Women with strongly ER positive tumours may benefit more from goserelin treatment. The combination of goserelin and tamoxifen is not superior to either modality alone. With the limitations of a subset trial, these data have to be interpreted cautiously.

show abstract

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98

Abstract: Central review changed the assessment of receptor status in a substantial proportion of patients, and should be performed whenever possible in similar trials. PgR expression did not affect the relative efficacy of letrozole over tamoxifen.

Cited by 404 publications

References 24 publications

A Review of an Unfavorable Subset of Breast Cancer: Estrogen Receptor Positive Progesterone Receptor Negative

A Review of an Unfavorable Subset of Breast Cancer: Estrogen Receptor Positive Progesterone Receptor Negative

Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence

Contact Info

Product

Resources

About